Humulin M3 (Mixture 3)

Humulin M3 (Mixture 3) is a prescription insulin product that contains recombinant human insulin as its active ingredient. It is supplied as a subcutaneous injectable solution, with a strength that varies according to regional labeling. Marketed in the European Union, Humulin M3 belongs to the insulin class of antidiabetic agents and is used to help regulate blood glucose in patients with diabetes mellitus type 1 or type 2.

Humulin M3 is indicated for the management of hyperglycemia in adults with diabetes mellitus.

- Used in type 1 diabetes as part of a basal‑bolus insulin regimen. - Used in type 2 diabetes when oral agents and lifestyle measures do not achieve target glucose levels. - Provides a mixed insulin profile that combines rapid‑acting and intermediate‑acting components. - Can be administered alongside diet and exercise to improve overall glycemic control. - May be considered when a single‑dose mixed insulin simplifies the injection schedule.

Adverse reactions to Humulin M3 may vary in frequency and severity.

Common: - Hypoglycemia, particularly if meals are missed or delayed. - Redness, swelling, or itching at the injection site. - Gradual weight gain associated with improved glucose utilization.

Serious: - Severe hypoglycemia causing loss of consciousness or seizures. - Anaphylactic or systemic allergic reactions. - Marked edema or fluid retention.

When prescribing or using Humulin M3, several precautions should be considered to minimize risk.

- Monitor blood glucose regularly, especially during dose adjustments. - Adjust dosage in patients with renal or hepatic impairment. - Use with caution during pregnancy and lactation; weigh maternal benefits against potential fetal risks. - Avoid use in individuals with known hypersensitivity to human insulin or any excipients. - Educate patients on recognizing and treating hypoglycemia promptly. - Consider lower starting doses for elderly or frail patients.

Humulin M3 can interact with other medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid: - Concurrent use of other rapid‑acting insulins or insulin analogues without dose adjustment. - Beta‑blockers that may mask hypoglycemia symptoms. - Monoamine oxidase‑A (MAO‑A) inhibitors that can potentiate insulin’s effect.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) may increase hypoglycemia risk. - Corticosteroids, thiazide diuretics, or sympathomimetics can raise blood glucose, requiring dose adjustments. - Alcohol consumption can potentiate insulin‑induced hypoglycemia.